A dose-ranging phase I study of dextrin sulphate, a vaginal microbicide, in HIV-negative and HIV-positive female volunteers

Sheena McCormack, Vicky Jespers, Naomi Low-Beer, Rhian Gabe, Nicola Kaganson, Alan Chapman, Andrew Nunn, Charles Lacey, Lut Van Damme

Research output: Contribution to journalArticlepeer-review


This phase I dose-ranging study of 2 weeks of twice-daily dextrin sulphate (DS), a sulphated polymer with in vitro activity against HIV, was designed in 2 parts. Part A was a randomized, placebo-controlled, double-blind, 3-arm trial (DS4%, DS1%, placebo) in HIV-negative women. In part B, HIV-positive women received DS4% and HIV-negative women were randomized to DS4% or no gel.
Original languageEnglish
Pages (from-to)765-70
Number of pages6
JournalSexually transmitted diseases
Issue number12
Publication statusPublished - 2005


  • Administration, Intravaginal
  • Adult
  • Anti-Infective Agents
  • Cote d'Ivoire
  • Dextrins
  • Double-Blind Method
  • Female
  • Gels
  • HIV
  • HIV Seronegativity
  • HIV Seropositivity
  • Humans
  • Middle Aged
  • Sexual Behavior
  • Treatment Outcome
  • Uganda

Cite this